From: Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer
Methylation monitoring
n
BMP3m
NPTX2m
SPARCm
SFRP1m
TFPI2m
To diagnosis
8
5 (62.5%)
7 (87.5%)
1 (12.5%)
After treatment
24
4 (16.67%)
16 (66.67%)
1 (4.17%)
3 (12.5%)